Welcome to our dedicated page for Elutia SEC filings (Ticker: ELUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elutia Inc. (ELUT) SEC filings page on Stock Titan centralizes the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret complex documents. Elutia is a regenerative medicine company that develops drug-eluting biomatrix products, and its filings provide detailed insight into how this business is structured, financed and governed.
Key documents for ELUT include Form 10-K annual reports and Form 10-Q quarterly reports, which discuss Elutia’s drug-eluting biomatrix platform, segment information such as historical Device Protection, Women’s Health and Cardiovascular activities, risk factors, and management’s analysis of operating performance. These reports also describe the company’s focus on NXT-41 and NXT-41x in plastic and reconstructive surgery and summarize prior divestitures, including the Orthobiologics business and the CIED/BioEnvelope business.
Elutia files frequent Form 8-K current reports to document material events. Recent 8-Ks have covered the agreement and closing of the sale of its CIED business to Boston Scientific and Cardiac Pacemakers Inc., amendments to its credit facility with SWK Funding LLC, the use of sale proceeds to repay that facility, board changes, and a Nasdaq notice regarding minimum bid price compliance. These filings also attach press releases with financial results and transaction details, giving additional context on cash flows, debt reduction and strategic focus.
Investors can also use this page to access proxy and governance filings when available, as well as any Form 4 insider transaction reports that disclose trades by directors and officers. Stock Titan’s AI features summarize lengthy filings, highlight sections on regulatory risk, litigation related to products such as FiberCel, royalty and revenue interest obligations, and explain how transactions like the BioEnvelope sale affect Elutia’s balance sheet and future plans.
By reviewing ELUT’s SEC filings alongside AI-generated explanations, users can quickly understand the regulatory history, capital structure changes and strategic decisions that shape Elutia’s drug-eluting biomatrix business.
Knollwood Investment Advisory, LLC has filed a Schedule 13G reporting beneficial ownership of 2,556,724 shares of Elutia Inc. Class A Common Stock, representing 6.3% of the class as of 12/31/2025.
Knollwood reports sole voting and sole dispositive power over all 2,556,724 shares, with no shared voting or dispositive power. The firm states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Elutia Inc.
Elutia Inc. insider Kevin L. Rakin and affiliated HighCape entities reported recent share activity in Elutia Class A Common Stock. On January 30, 2026, a reporting person purchased 70,000 shares at a weighted average price of $1.06 per share, with individual trade prices ranging from $1.05 to $1.08. Following this purchase, 196,120 shares were held directly. The filing also reports 322,419 shares held indirectly by trusts and 4,706,559 shares indirectly held through HighCape-related entities, which may be deemed beneficially owned as described in the footnotes, subject to customary beneficial ownership disclaimers.
Elutia Inc. director Guido J. Neels reported an open-market purchase of Class A common stock. On January 30, 2026, he bought 20,000 shares of Elutia at a weighted average price of $1.04 per share, with individual trade prices ranging from $1.03 to $1.07. Following this transaction, he beneficially owned 118,750 shares of Elutia Class A common stock held directly.
Elutia Inc. director Guido J. Neels reported open-market purchases of the company’s Class A common stock on two consecutive days. On January 28, 2026, he bought 15,000 shares at a weighted average price of $1.06, with individual trades ranging from $1.00 to $1.10, bringing his holdings to 83,750 shares.
On January 29, 2026, he purchased another 15,000 shares at a weighted average price of $1.06, from $1.03 to $1.10 per share. After these transactions, Neels directly owned 98,750 Class A common shares of Elutia Inc.
Elutia Inc. (ELUT) received an updated ownership report from AIGH-related entities. AIGH Capital Management LLC, AIGH Investment Partners LLC and Orin Hirschman together report beneficial ownership of 3,068,185 shares of Elutia common stock, representing 7.6% of the class as of the event date.
The filing notes sole voting and dispositive power over these 3,068,185 shares and no shared power. It also states that this percentage excludes warrants to purchase 1,300,000 additional shares that are not currently exercisable because of beneficial ownership limitations. The reporting holders certify the position is held in the ordinary course and not to change or influence control.
Elutia Inc. reported that it has issued a press release with preliminary financial results for the fourth quarter ended December 31, 2025. These preliminary figures are still subject to normal year-end accounting close and audit procedures, so final results may differ once the review is complete.
The company furnished the press release as an exhibit to the current report, making an early view of its quarter available while clarifying that this information is being provided for disclosure purposes and is not treated as formally filed under certain Exchange Act liability provisions.
Elutia Inc. director reports open-market share purchase
A director of Elutia Inc. (ELUT) reported buying Class A common stock in a personal capacity. On 12/17/2025, the reporting person purchased 12,500 shares of Elutia Class A common stock at a price of $0.51 per share. After this transaction, the director beneficially owned 31,098 shares of Class A common stock held directly.
Elutia Inc. director Brigid Makes reported an open-market purchase of Class A common stock. On 12/17/2025, the reporting person bought 25,000 Class A shares at a weighted average price of $0.52 per share, with individual trade prices ranging from $0.51 to $0.53. After this transaction, the director beneficially owns 27,000 Class A shares, held directly. The filing notes that detailed trade-by-trade pricing within the reported range is available upon request.
Elutia Inc. insider C. Randal Mills, who serves as president, CEO, and director, reported buying additional company stock. On 12/17/2025, he acquired 3,000 shares of Elutia Class A common stock in an open-market purchase at $0.51 per share. Following this transaction, he directly beneficially owns 379,204 shares of the company’s Class A common stock.
Elutia Inc.'s Chief Financial Officer, Matthew Ferguson, reported buying additional company stock. On 12/17/2025, he purchased 60,000 shares of Elutia Inc. Class A common stock in an open market transaction coded as a purchase, at a weighted average price of $0.53 per share, with individual trade prices ranging from $0.51 to $0.54.
Following this transaction, Ferguson beneficially owns 447,110 shares of Elutia Inc. common stock, held directly. The filing notes that detailed breakdowns of the number of shares purchased at each separate price within the reported range are available upon request to the company, any security holder, or SEC staff.